- Home
- HQL vs AUTL Comparison
HQL vs AUTL Comparison
Compare HQL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- AUTL
- Stock Information
- Founded
- HQL 1992
- AUTL 2014
- Country
- HQL United States
- AUTL United Kingdom
- Employees
- HQL N/A
- AUTL N/A
- Industry
- HQL Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQL Finance
- AUTL Health Care
- Exchange
- HQL Nasdaq
- AUTL Nasdaq
- Market Cap
- HQL 440.3M
- AUTL 368.6M
- IPO Year
- HQL N/A
- AUTL 2018
- Fundamental
- Price
- HQL $16.88
- AUTL $1.28
- Analyst Decision
- HQL
- AUTL Strong Buy
- Analyst Count
- HQL 0
- AUTL 5
- Target Price
- HQL N/A
- AUTL $9.12
- AVG Volume (30 Days)
- HQL 120.9K
- AUTL 2.3M
- Earning Date
- HQL 01-01-0001
- AUTL 11-12-2025
- Dividend Yield
- HQL 11.56%
- AUTL N/A
- EPS Growth
- HQL N/A
- AUTL N/A
- EPS
- HQL 0.79
- AUTL N/A
- Revenue
- HQL N/A
- AUTL $29,934,000.00
- Revenue This Year
- HQL N/A
- AUTL $643.50
- Revenue Next Year
- HQL N/A
- AUTL $108.69
- P/E Ratio
- HQL $17.08
- AUTL N/A
- Revenue Growth
- HQL N/A
- AUTL 185.17
- 52 Week Low
- HQL $11.34
- AUTL $1.11
- 52 Week High
- HQL $14.37
- AUTL $3.72
- Technical
- Relative Strength Index (RSI)
- HQL 56.19
- AUTL 37.95
- Support Level
- HQL $15.67
- AUTL $1.23
- Resistance Level
- HQL $17.10
- AUTL $1.52
- Average True Range (ATR)
- HQL 0.39
- AUTL 0.11
- MACD
- HQL -0.11
- AUTL -0.02
- Stochastic Oscillator
- HQL 55.50
- AUTL 5.75
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.